US Bancorp DE Acquires 4,232 Shares of Evolent Health, Inc. (NYSE:EVH)

US Bancorp DE lifted its holdings in shares of Evolent Health, Inc. (NYSE:EVH) by 180.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 6,579 shares of the technology company’s stock after purchasing an additional 4,232 shares during the quarter. US Bancorp DE’s holdings in Evolent Health were worth $186,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Values First Advisors Inc. boosted its holdings in Evolent Health by 21.0% in the third quarter. Values First Advisors Inc. now owns 32,129 shares of the technology company’s stock worth $909,000 after purchasing an additional 5,583 shares in the last quarter. Moody Aldrich Partners LLC bought a new stake in shares of Evolent Health during the 3rd quarter worth about $1,421,000. Friedenthal Financial acquired a new position in shares of Evolent Health during the 3rd quarter valued at about $723,000. Creative Planning increased its holdings in shares of Evolent Health by 139.1% during the 3rd quarter. Creative Planning now owns 43,262 shares of the technology company’s stock valued at $1,223,000 after acquiring an additional 25,171 shares during the last quarter. Finally, GAMMA Investing LLC raised its stake in shares of Evolent Health by 5,365.5% in the 3rd quarter. GAMMA Investing LLC now owns 1,585 shares of the technology company’s stock valued at $45,000 after acquiring an additional 1,556 shares in the last quarter.

Analysts Set New Price Targets

Several brokerages have commented on EVH. JMP Securities lowered their price target on Evolent Health from $34.00 to $31.00 and set a “market outperform” rating on the stock in a report on Friday, August 9th. Oppenheimer lowered their target price on shares of Evolent Health from $45.00 to $34.00 and set an “outperform” rating on the stock in a research note on Friday, November 8th. Royal Bank of Canada reissued an “outperform” rating and set a $20.00 target price on shares of Evolent Health in a research report on Tuesday. Citigroup lowered their price target on Evolent Health from $33.00 to $21.00 and set a “buy” rating on the stock in a research report on Wednesday. Finally, JPMorgan Chase & Co. boosted their price objective on Evolent Health from $36.00 to $45.00 and gave the stock an “overweight” rating in a research report on Monday, August 19th. One analyst has rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Evolent Health has a consensus rating of “Buy” and a consensus price target of $29.50.

Insider Activity at Evolent Health

In other Evolent Health news, CEO Seth Blackley sold 187,904 shares of Evolent Health stock in a transaction that occurred on Thursday, August 22nd. The stock was sold at an average price of $30.00, for a total transaction of $5,637,120.00. Following the sale, the chief executive officer now directly owns 411,924 shares of the company’s stock, valued at approximately $12,357,720. The trade was a 31.33 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Emily Ann Rafferty sold 8,861 shares of the company’s stock in a transaction that occurred on Thursday, August 22nd. The shares were sold at an average price of $30.00, for a total value of $265,830.00. Following the completion of the sale, the chief operating officer now owns 63,408 shares in the company, valued at approximately $1,902,240. This represents a 12.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 307,291 shares of company stock worth $9,290,385. 1.60% of the stock is owned by corporate insiders.

Evolent Health Price Performance

Shares of EVH stock opened at $12.67 on Friday. Evolent Health, Inc. has a 12 month low of $12.31 and a 12 month high of $35.00. The company has a market capitalization of $1.47 billion, a P/E ratio of -13.92 and a beta of 1.58. The stock has a 50 day moving average of $25.47 and a two-hundred day moving average of $24.45. The company has a current ratio of 1.04, a quick ratio of 1.08 and a debt-to-equity ratio of 0.58.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.